These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15825162

  • 21. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma.
    Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, Valente M, Nitti D, Gatta A, Fassina G.
    Br J Cancer; 2004 Feb 23; 90(4):833-7. PubMed ID: 14970861
    [Abstract] [Full Text] [Related]

  • 22. Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis.
    Liu CH, Gil-Gómez A, Ampuero J, Romero-Gómez M.
    Liver Int; 2018 Oct 23; 38(10):1820-1831. PubMed ID: 29704434
    [Abstract] [Full Text] [Related]

  • 23. Squamous cell carcinoma antigen 1 and 2 mRNA and a new variant expressed in hepatocellular carcinoma.
    Li S, Gao Y, Yang B, Liang Z, Wang Y, Zhai D, Jing L, Liu T, Wang F, DU Z, Wang Y.
    Neoplasma; 2014 Oct 23; 61(6):718-23. PubMed ID: 25150316
    [Abstract] [Full Text] [Related]

  • 24. Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma.
    Soyemi OM, Otegbayo JA, Ola SO, Akere A, Soyemi T.
    BMC Res Notes; 2012 Aug 03; 5():403. PubMed ID: 22856336
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma.
    Eisa NH, Ebrahim MA, Ragab M, Eissa LA, El-Gayar AM.
    J Oncol Pharm Pract; 2015 Oct 03; 21(5):323-30. PubMed ID: 24769518
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Analysis of the Squamous Cell Carcinoma Antigen (SCCA) Which Has a Significant Difference in Values between CLIA and FEIA--Case Report of Extra Glycosylation in SCCA].
    Maruyama K, Aoki Y, Yamanaka M, Ono M, Hotta T, Kang D.
    Rinsho Byori; 2016 Mar 03; 64(3):265-9. PubMed ID: 27363218
    [Abstract] [Full Text] [Related]

  • 31. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
    Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC.
    Clin Cancer Res; 2008 Aug 01; 14(15):4814-20. PubMed ID: 18676753
    [Abstract] [Full Text] [Related]

  • 32. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
    Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y.
    Anticancer Res; 2013 Mar 01; 33(3):1013-21. PubMed ID: 23482775
    [Abstract] [Full Text] [Related]

  • 33. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
    Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W.
    Lancet Oncol; 2012 Aug 01; 13(8):817-26. PubMed ID: 22738799
    [Abstract] [Full Text] [Related]

  • 34. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P.
    J Gastroenterol Hepatol; 2010 Jan 01; 25(1):129-37. PubMed ID: 19793164
    [Abstract] [Full Text] [Related]

  • 35. Hepatocellualar carcinoma serum markers.
    Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS.
    Semin Oncol; 2012 Aug 01; 39(4):410-33. PubMed ID: 22846859
    [Abstract] [Full Text] [Related]

  • 36. The value of squamous cell carcinoma antigen (SCCa) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review.
    Zhou Z, Li W, Zhang F, Hu K.
    PLoS One; 2017 Aug 01; 12(12):e0186165. PubMed ID: 29227998
    [Abstract] [Full Text] [Related]

  • 37. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
    Wen Y, Han J, Chen J, Dong J, Xia Y, Liu J, Jiang Y, Dai J, Lu J, Jin G, Han J, Wei Q, Shen H, Sun B, Hu Z.
    Int J Cancer; 2015 Oct 01; 137(7):1679-90. PubMed ID: 25845839
    [Abstract] [Full Text] [Related]

  • 38. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences.
    Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F.
    Biomark Med; 2020 Jul 01; 14(10):855-867. PubMed ID: 32808827
    [Abstract] [Full Text] [Related]

  • 39. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
    Jin GZ, Yu WL, Dong H, Zhou WP, Gu YJ, Yu H, Yu H, Lu XY, Xian ZH, Liu YK, Cong WM, Wu MC.
    J Hepatol; 2013 Sep 01; 59(3):510-7. PubMed ID: 23665285
    [Abstract] [Full Text] [Related]

  • 40. IgM-linked SerpinB3 and SerpinB4 in sera of patients with chronic liver disease.
    Biasiolo A, Tono N, Ruvoletto M, Quarta S, Turato C, Villano G, Beneduce L, Fassina G, Merkel C, Gatta A, Pontisso P.
    PLoS One; 2012 Sep 01; 7(7):e40658. PubMed ID: 22808225
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.